UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients
Brussels (ots/PRNewswire) - - The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan , a peptide inhibitor of complement component 5 (C5) currently in phase 3, to the UCB pipeline alongside rozanolixizumab , UCB's FcRn targeting ...